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Abstract
Background
Although increased prevalence of transfusion transmissible infections (TTI) among “men
who have sex with men” (MSM) has been well documented, the exclusion of MSM as blood
donors is contested. The aim of this systematic review is to find studies that describe the
risk of TTI in MSM blood donors.
Methods
We searched MEDLINE, Embase, The Cochrane Central Register of Controlled Trials,
Cinahl, and Web of Science, and used GRADE for determining evidence quality. We includ-
ed studies comparing MSM and non-MSM blood donors (or people eligible to give blood),
living in areas most relevant for our Blood Service.
Results
Out of 18 987 articles, 14 observational studies were included. Two studies directly com-
pared MSMwith non-MSM donors showing that MSM donors have a statistically significant
higher risk of HIV-1 infections. In one of these studies it was shown that this was related to
recent (< 12 months) MSM contact. In two additional studies no evidence was shown in fa-
vour of a certain deferral period for MSM. Ten studies, applying permanent deferral for
MSM, compared infected versus non-infected donors. One study found that MSM is a statis-
tically significant risk factor for HIV-1 infection in blood donors. For other TTI such as HBV
or HCV, an increased risk of infection could not be demonstrated, because the precision of
the results was affected by the low numbers of donors with MSM as risk factor, or because
of risk of bias in the included studies. All studies included low level evidence, because of
risk of bias and imprecision of the results.
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Conclusions
High-quality studies investigating the risk of TTI in MSM who donate blood are scarce. The
available evidence suggests a link between MSM blood donors and HIV-1 infection, but is
too limited to be able to unambiguously/clearly recommend a certain deferral policy.
Background
In order to guarantee a safe blood supply blood donors must meet certain eligibility require-
ments. Eligibility is determined through the donor history questionnaire and interview, assess-
ing risk factors for transfusion transmissible infections (TTI) such as tattooing, injecting drugs,
and sexual behaviour such as “men who have sex with other men” (MSM). MSM have the
highest prevalence of human immunodeficiency virus (HIV) in the Western world, with rising
incidence in many countries. Other sexually transmitted diseases (STD) which are also trans-
missible via blood or transfusion, are hepatitis B and hepatitis C, with a high prevalence of hep-
atitis B virus (HBV) infection in MSM and a rising incidence of hepatitis C virus (HCV)
infection in HIV-infected MSM. In addition, recent increases of syphilis in MSM have been
documented, and MSM are also more often diagnosed with other STDs which are transfusion
transmissible, such as chlamydia [1,2]. Whether that in itself justifies excluding MSM from do-
nating blood has been the subject of public dispute, the question being whether the risk of in-
fection is high enough to support exclusion, and if so for how long [3,4]? One side brands the
measures as discriminatory against gay men [5]. The other side argues that exclusion is based
on MSM behaviour rather than sexual orientation, that the epidemiology of TTI is clear, and
that the right of the patient to receive safe blood takes precedence over the wish of a particular
donor group to be allowed to donate blood [6]. Measures differ widely between countries, rang-
ing from lifelong to a five or one year exclusion, or even no exclusion at all [7].
This article is the first systematic review on this topic, and uses the principles of Evidence-
Based Medicine at its most rigorous level, by applying the methodology of the Cochrane Col-
laboration [8]. The aim was to find studies that describe the relationship between MSM and
safe blood donation, not the prevalence of TTI in MSM in general for which systematic reviews
already exist [1]. The following ‘PICO’ question was developed: For male blood donors (Popu-
lation) is having sex with other men (Intervention) a risk factor for TTI (Outcome) compared
to not having sex with other men (Comparison) in Western countries?
Methods
We followed the PRISMA statement for the reporting of this systematic review [9]. No protocol
for this systematic review existed or was published beforehand.
Selection criteria
We used the following inclusion and exclusion criteria for the selection of articles:
Population: Inclusion: blood donors (or people eligible to give blood), living in areas most
relevant for our Blood Service: Northern, Western, and Southern Europe (Albania, Andorra,
Austria, Belgium, Bosnia and Herzegovina, Croatia, Denmark, Estonia, Finland, France, Ger-
many, Gibraltar, Greece, Iceland, Italy, Ireland, Kosovo, Latvia, Liechtenstein, Lithuania, Lux-
embourg, Macedonia, Malta, Monaco, Montenegro, the Netherlands, Norway, Portugal, San
Marino, Serbia, Slovenia, Spain, Sweden, Switzerland, Vatican City), USA, Canada, Australia,
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New-Zealand; Exclusion: a population containing blood donors, but not exclusively consisting
of blood donors.
Intervention/Risk factor: Inclusion: men having sex with other men after 1977.
Comparison: Inclusion: men not having sex with other men.
Outcome: Inclusion: markers of transfusion-transmissible infections from the following
pathogenic micro-organisms in the donor blood (which are sexually transmitted and also
transfusion transmissible): HIV, HBV, HCV, Chlamydia, and Treponema pallidum (causing
syphilis).
Study design: Inclusion: Intervention studies: randomized controlled trials, controlled clini-
cal trials, before- and after studies; Observational studies: cohort studies, case-control studies,
cross-sectional studies (surveys); these study types are included independently of the potential
risk of bias (however, risk of bias will transparently be reported); Exclusion: non-controlled
studies, case reports, case series, letters, comments, opinion pieces, narrative reviews,
modelling studies.
No language criteria were used.
Search strategy and study selection
There are three types of studies that can potentially answer our question: (1) “Type 1 studies”
comparing the incidence of TTI in blood products of MSM and non-MSM donors, (2) “Type 2
studies” comparing two types of deferral strategies for MSM donors, (3) “Type 3 studies” com-
paring infected blood donors (cases) versus non-infected blood donors (controls), identifying
risk factors (e.g. MSM) of both groups (case-control studies).
Search strategies were composed to retrieve the three study types. The following databases
were searched from their date of inception to 26 March 2014: MEDLINE (using the PubMed
interface), Embase (using the Embase.com interface), The Cochrane Central Register of Con-
trolled Trials, Cinahl, and Web of Science. Full details of the search strategies are given in S1
File. Study selection was performed in parallel by two independent reviewers (EDB, TD). Titles
and abstracts of the studies identified by the search were scanned. When a relevant article was
found, full text articles were retrieved. Studies that did not meet the selection criteria were ex-
cluded. The citation and reference lists of included studies were searched, and the first 20 relat-
ed items in PubMed were scanned for other potentially relevant studies. Any discrepancies
among the two reviewers were resolved by consensus.
Data collection
Data concerning study design, study population, outcome measures (markers of transfusion-
transmissible infections expressed as risk ratio, odds ratio or incidence rate ratio), and study
quality were extracted independently by two reviewers (EDB, TD). In the event that data were
lacking, authors were contacted to obtain more detailed information. No statistical methods
were used to pool the data because of heterogeneity of the studies.
Quality of evidence
The GRADE approach was used to assess the overall quality of evidence included in this review
and the online available Guideline Development Tool (GDT), developed by the GRADEWork-
ing Group, was used to develop the GRADE table, including quality assessment and a summary
of findings (http://www.guidelinedevelopment.org/). This table was adapted manually in case
our data were not compatible with the template. A level of evidence was assigned for each out-
come, which were all rated as critical outcomes. GRADE downgrades the level of evidence be-
cause of risk of bias (limitations in study design) of the included studies, inconsistency between
MSMBlood Donors and TTI
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results of different studies (due to differences in populations, interventions or outcomes), indi-
rectness (of population, intervention or outcome), imprecision and publication bias. All studies
included in this systematic review were observational studies, which results in an initial “low
level of evidence” according to the GRADE approach. For none of the observational studies in-
cluded there were reasons to upgrade the level of evidence. Risk of bias in the individual studies
was analysed at the study level by evaluating the presence of eligibility criteria, adequate control
of confounding, follow-up and correct measurement of exposure and outcome, as detailed in
the Help section of the GDT [10].
Results
Study selection and study characteristics
Fig 1 provides a flowchart of the identification and selection of studies. The searches yielded
18,987 references. After removing duplicates and screening relevant titles and abstracts, 317
references were selected by reviewer 1 and 418 references by reviewer 2 for which the full text
was evaluated. In S1 Table an overview is given of all studies excluded by at least one of the re-
viewers, with the reason for exclusion. The major reason for exclusion was study design (56%)
as many references were opinion pieces, letters, comments or uncontrolled studies. After re-
solving disagreements among the two reviewers, we retained 14 observational studies (no refer-
ences of a higher study design were found), which are described below and in detail in Table 1.
Type 1 studies: comparison of TTI in MSM vs non-MSM donors. In two studies com-
paring MSM and non-MSM donors, TTI were searched for in respectively 25,168 male blood
donors with different time intervals since the last MSM contact (self-reported in an anonymous
mail survey) versus control donors, and in 52 MSM-donors who were eligible as blood donors
versus 209 non-MSM blood donors [12,19].
Type 2 studies: comparison of TTI between different deferral strategies for MSM do-
nors. Two studies compared different deferral strategies [20,22]. In the first study blood sam-
ples from donors, including MSM, were examined for HIV prevalence during the five years
preceding and the five years following a change from a permanent/five-year deferral versus a
one-year deferral for MSM [20]. The second study compared permanent deferral for MSM do-
nors, with individual risk assessment of sexual behaviours [22].
Type 3 studies: comparison of infected vs non-infected blood donors for risk fac-
tors. 10 case-control studies tried to identify risk factors for TTI in blood donors. The cases
included blood donors with a viral infection with HIV-1 [13], HBV [14,16], or HCV
[11,15,17,18,21,23,24], and the controls were donors who did not have this particular infection.
Studies only looking at blood donors with infections were not included. Two of the 10 studies,
where “homosexuality” was measured as a risk factor, did not explicitly mention if this con-
cerned only men, but we assumed this was the case [21,23]. The majority of studies did not ex-
plicitly mention which donor selection strategy was in place with regards to MSM at the time
of the study, however from other references we know that all studies had a policy of lifelong ex-
clusion at the time of the study [7,20].
Synthesis of findings
An overview of the synthesis of findings of all included studies can be found in Table 2. Since
we were not able to pool any studies, a narrative overview of the results of the individual studies
is given below
Type 1 studies: comparison of TTI in MSM vs non-MSM donors. There is limited evi-
dence (in number and quality) from two observational studies from 1985 and 2005, that male
blood donors who had sex with other men after 1977 have a statistically significant higher risk
MSMBlood Donors and TTI
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Fig 1. PRISMA flowchart of identification and selection of studies.
doi:10.1371/journal.pone.0122523.g001
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Table 1. Characteristics of included studies.
Author, Year,
Country
Study design Population Comparison/Risk factor Remarks
Allison, 2012,
United States
[11]
Observational
study: case-control
469 true HCV positive volunteer
blood donors; 217 false HCV
positive volunteer blood donors; 52
indeterminate HCV positive
volunteer bloods
Risk factor: Men who have sex
with other men
All subjects had positive anti-HCV
ﬁndings by EIA. Donors with
positive results of RIBA are
considered infected with HCV
Alpaugh 1985,
United States
[12]
Observational
study: cohort study
68 homosexuals, of which 52 were
eligible donors on the basis of their
medical history, and 209 random
blood donors
Homosexuals versus non-
homosexuals
Risk factor analysis was done only
with the homosexuals who were
eligible donors on the basis of their
medical history. HBV was
measured using anti-HBc testing
(Corzyme EIA test) and HBsAg
testing (Ayszyme II test).
Busch, 1994,
United States
[13]
Observational
study: case-control
Blood donors: 146 HIV-1 infected
cases and 151 uninfected controls
enrolled; 129 and 131 replied
Risk factor: Males having sexual
contact with males
HIV-1 positive was deﬁned as
positive in EIA, protein immunoblot
and RIP
Christensen,
2001, Denmark
[14]
Observational
study: case-control
Registered blood donors (in 1997):
44 conﬁrmed anti-HBc positive
cases; 585 anti-HBc negative
controls
Risk factor: Homosexual/bisexual
male contact
Kaldor, 1992,
Australia [15]
Observational
study: case-control
Blood donors in Sydney: 220 HCV
infected cases (142 male, 78
female); 210 HCV uninfected
controls (126 male, 84 female)
Risk factor: Homosexual (male) HCV positive was deﬁned as
positive in two ELISAs, RIBA-2
and PCR.
Moore, 1997,
United Kingdom
[16]
Observational
study: case-control
Blood donors (in 1993): 35 conﬁrmed
anti-HBc positive donors; 50 anti-
HBc negative donors, of which 11
attended for interview
Risk factor: Men with homosexual
partners
A group of conﬁrmed anti-HBc
positive cases excluded before
donation for other reasons, were
not included in our analysis.
Murphy, 2000,
United States
[17]
Observational
study: case-control
Blood donors in 5 US Centres: 758
HCV infected cases; 1039 HCV
uninfected controls
Risk factor: Men who have sex
with (at least one) other men
HCV positive was deﬁned as
positive in ELISA assay and RIBA.
Neal, 1994,
United Kingdom
[18]
Observational
study: case-control
Blood donors in Trent: 74 HCV
infected cases (142 male, 78
female); 150 HCV uninfected
controls (126 male, 84 female)
Risk factor: Homosexual (male) HCV positive was deﬁned as
positive in ELISA assay and RIBA-
2.
Sanchez 2005,
United States
[19]
Observational
study:cross-
sectional (survey)
25168 male blood donors MSM vs. non-MSM donors;
different periods since last MSM
contact (self-reported in
anonymous mail survey)
Outcome: Risk of TTI (reactive
screening test result for HBc
antigen, syphilis, HIV, human T-
lymphotropic virus, HCV, HBs
antigen, and ALAT)
Seed, 2010,
Australia [20]
Observational
study: before and
after study
4,025,571 donations in 5-year period
preceding implementation of
12-month MSM deferral and
4,964,628 donations in 5-year period
post-implementation
HIV-positive male donors before
and after implementation of
12-month deferral for MSM donors
Serfaty, 1993,
France [21]
Observational
study: case-control
Blood donors with no history of
transfusion or IDU: 35 HCV infected
cases; 35 HCV uninfected controls
Risk factor: Homosexual HCV positive was deﬁned as
positive in ELISA assay and RIBA-
2.
Suligoi, 2013,
Italy [22]
Observational
study: before and
after study
868,391 blood donors in 1999,
1,794,436 blood donors in 2009 and
1,840,464 blood donors in 2010
HIV-positive donors reporting
MSM in a permanent deferral
period (1999) versus a period of
individual risk assessment (2009
and 2010)
Tullen, 1993,
Switzerland [23]
Observational
study: case-control
Blood donors: 68 HCV infected
cases; 103 HCV uninfected controls
Risk factor: Homosexual HCV positive was deﬁned as
positive in ELISA assay and
RT-PCR. Controls had high ALAT
levels.
(Continued)
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of HIV-1, compared to male blood donors who did not have sex with other men [12,19]. The
study of Alpaugh et al. found a risk ratio of 9.19, 95% CI 3.99–21.17 for the presence of anti-
body to hepatitis B core antigen (HBc) [12]. In this study the presence of antibodies to HBc
was used to measure HBV infection. However this is an older test with poor specificity, which
means that a high percentage of HBV negatives is incorrectly identified as HBV positives. Be-
cause results of this study are influenced by the test that was used to measure the outcome, we
did not take the HBV data—in contrast to its HIV data—into account into our final conclusion
[25]. For the presence of antibody to human T Cell Lymphotropic virus type III antigen (=
HIV-1), the risk ratio was 6.90, 95% CI 2.10–22.68 for the initial reactive test, and 27.60, 95%
CI 3.47–219.37 for the repeatable reactive test [12]. In the study by Sanchez et al., including
25,168 male donors, 6% of the donors who had sex with other men after 1977 had reactive
screening test results, versus 1.7% of non-MSM donors, which was statistically significant.
Analysis of the subpopulation between 1977 and 2010 indicated that the statistically significant
difference was due to the MSM population with recent (< 12 months) sexual contact [19]. A
statistically significant increased risk of infections could not be demonstrated for male blood
donors who had sex with other men before 1977 (2.8% of MSM donors versus 1.7% of non-
MSM donors) or for MSMmore than one year ago since 1977, due to a large variability of the
results (wide confidence intervals) [19].
Type 2 studies: comparison of TTI between different deferral strategies for MSM do-
nors. In two studies, from 2010 and 2013, no statistically significant differences between
types of deferral policy were measured [20,22]. In the first study, no statistically significant
change in the number of HIV-positive male donors when applying a five versus a one year de-
ferral period could be demonstrated. In the same study, the number of HIV-positive donors
with MSM as a risk factor was also measured, however the number of male donors who dis-
closed risk factors is not known, and thus no conclusions can be made of these data [20]. In the
second study, no statistically significant difference in the number of HIV-positive MSM donors
could be demonstrated when a permanent deferral was changed to an individual risk assess-
ment of sexual behaviours [22]. The results of these studies cannot be considered precise as the
number of HIV-infected donors was too low [20,22].
Type 3 studies: comparison of infected vs non-infected blood donors for risk factors.
Ten case-control studies investigated whether MSM is a risk factor for TTI such as HIV-1,
HBV, or HCV in blood donors, comparing the risk profile of donors with TTI and matched
healthy donors. All studies were performed when a permanent deferral strategy for MSM was
in place, and thus any cases would have occurred despite this deferral strategy.
Table 1. (Continued)
Author, Year,
Country
Study design Population Comparison/Risk factor Remarks
Van der Poel,
1991, the
Netherlands [24]
Observational
study: case-control
Blood donors in Amsterdam: 12 HCV
infected cases; 113 HCV uninfected
controls
Risk factor: Homosexual (male) HCV positive was deﬁned as
positive in ELISA assay and
4-RIBA and PCR. All subjects had
positive anti-HCV ﬁndings by
ELISA.
ALAT: alanine aminotransferase; EIA: enzyme immunoassay; ELISA: enzyme-linked immunosorbent assay; HBc: hepatitis B core antigen; HBs: hepatitis
B surface antigen; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeﬁciency virus; IDU: intravenous drug use; MSM: men who have
sex with men; RIBA: recombinant immunoblot assay; RNA: ribonucleic acid; RIP: radioimmunoprecipitation; (RT)-PCR: (reverse transcriptase) polymerase
chain reaction; TTI: transfusion transmissible infections
doi:10.1371/journal.pone.0122523.t001
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There is limited evidence from one observational study, published in 1994, about the corre-
lation between MSM and the risk of HIV-1 infection in blood donors [13]. In this study it was
shown that MSM is a statistically significant risk factor for HIV-1 infection in blood donors, re-
porting an odds ratio of 45, 95% CI 10.66–189.84. However, the results cannot be considered
precise because of a low number of events (low number of donors with MSM as a risk factor
among the cases and controls) [13].
For the risk of HBV infection, we found limited evidence from 2 observational studies from
1997 and 2001, but a statistically significant correlation could not be demonstrated between
MSM and HBV infection in blood donors. The reason for this is a low number of events and a
large variability of the results, reflected in wide confidence intervals [14,16].
The majority of the studies were searching for MSM as a risk factor for HCV in blood do-
nors. A statistically significant increased risk of HCV-infection in blood donors could not be
demonstrated for MSM in six of these studies (all performed in the early ‘90s and one in 2000),
because of a low number of events (all studies) and/or a wide confidence interval
[15,17,18,21,23,24]. In one more recent (2012) study it was shown that MSM blood donors
have a statistically significant increased risk of HCV, reporting a risk ratio of 8.79, 95% CI
1.18–65.25, compared to non-MSM blood donors. However this risk ratio is a crude risk ratio,
which represents a correlation between HCV data and MSM, not taking into account that the
MSM donors could have other risk factors such as intravenous drug use or history of transfu-
sions. Since the latter risk factors are confounding variables and no measures were taken to
control for confounding in this study, this crude risk ratio, which we calculated ourselves based
on the raw data provided in the study, was not used as part of the evidence base [11].
Quality of the evidence
All studies included in this systematic review were observational studies, which results in an
initial “low level of evidence” according to the GRADE approach, and there were no reasons to
upgrade the level of evidence [10]. In order to determine the final level of evidence, first of all
the risk of bias was assessed at the individual study level. In all studies, risk of bias was found
because of limitations in study design or execution. For several studies there was no description
of possible confounders nor of the method that was used to adequately control for confounding
[11,12,14,15,20,22,24], or it was unclear if measures undertaken to adequately control for con-
founding were sufficient [17,18,21,23]. For 5 of the case-control studies inappropriate eligibility
criteria were used for the selection of cases and controls [11,16,23,24]. In 5 studies question-
naires were used [14,15,18,19,23] and in 2 studies interviews were performed [21,24] to obtain
information about risk factors, which is prone to recall bias. The studies by Seed et al. and Suli-
goi et al. are historically controlled, but groups where no change in deferral policy was imple-
mented were not included [20,22]. In addition in the study by Seed et al., different states/
territories had different policies ( 5 year deferral) before implementation of the new policy,
and implementation of the new policy did not occur at the same moment in each state/territory
[20]. In the study by Sanchez et al. and in the 11 case-control studies, donors who reported
MSM since 1977 were donating despite being excluded from this practice. It cannot be exclud-
ed that these donors may have different characteristics from men with a history of MSM since
1977 who did not donate because of the current policy, but would if it were changed [11,13–
19,21,23,24].
In addition to the risk of bias, the level of evidence was further downgraded because of im-
precision (low number of events, large confidence intervals and lack of data). There was no rea-
son to downgrade for inconsistency or indirectness. Overall, the strength of the body of
evidence, as defined by the GRADE approach, is “very low” for all outcomes, which means that
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the estimates of effect are uncertain and further research is very likely to have an important im-
pact on our confidence in the estimate of effect. An overview of how we obtained the level of
evidence for all outcomes is shown in Table 2.
Discussion
In this systematic review we searched for evidence on the association between MSM blood do-
nors and TTI. We identified 14 studies: two studies directly comparing MSM with non-MSM
donors, two studies comparing different types of deferral strategy for MSM and 10 studies
comparing infected versus non-infected donors during a permanent deferral policy for MSM.
Two studies however provided (statistically significant) data that were not taken into account
to formulate our conclusions: the HBV data in the study of Alpaugh et al. were measured with
an older diagnostic test with low specificity [12], and the HCV data in the study of Allison et al.
were not taking into account any confounding variables [11].
We identified 3 studies looking at the risk of HIV-1 infection in MSM versus non-MSM do-
nors. These studies showed a significant correlation between MSM and the risk of HIV-1 infec-
tion in blood donors. In addition, we found 3 studies looking at the risk of HBV infection and
7 studies looking at the risk of HCV infection, but none of these studies could demonstrate an
increased risk of infection.
The available evidence is too limited to be able to unambiguously/clearly recommend a cer-
tain deferral policy, however one study suggests exclusion of MSM donors for at least 1 year
after the last MSM contact. The latter however is based on very low level evidence from only 1
study and should therefore be interpreted with caution. This study showed that 8.3% of the do-
nors who had sex with other men the last 12 months had reactive screening test results, versus
1.7% of non-MSM donors [19]. We found no evidence that MSM blood donors are at a higher
risk of HBV and HCV infection. In the majority of the studies there was no information avail-
able about the period between the last MSM contact and the blood donation.
The main limitations of our analysis are:
1. the quality of the available evidence is defined according to the GRADE approach as “very
low”, because of the study design (observational studies), a low number of infected individu-
als, a low number of donors with MSM as a risk factor, and/or large confidence intervals.
Furthermore, the majority of the studies are older studies, including one study from 1985
and 7 studies from the early 1990s, which could result in bias since test specificity and sensi-
tivity has improved significantly since then.
2. our analysis does not account for (non-)compliance in filling out the donor history ques-
tionnaire, as it is impossible to deduce from the studies what percentage of donors were
honest about MSM behaviour, and of those who were not, what percentage were later forth-
right about this [26,27]. This in itself could compromise the quality of further studies. A re-
cent study from Australia confirmed high compliance to a 12-month deferral for MSM,
however compliance was calculated against the total population of male donors and not
against the population of MSM donors, and no comparison between different deferral strat-
egies was made [26]. High quality studies about the impact of different deferral strategies on
non-compliance are currently lacking.
3. our systematic review did not capture unpublished surveillance data that are probably being
collected by many blood services.
4. our analysis is limited to a certain geographic area, namely Western countries (Northern,
Western, and Southern Europe, USA, Canada, Australia, New-Zealand) as defined in the
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selection criteria, since the populations in these countries are most relevant for our Blood
Service. Because the epidemiology of STDs (which are also transfusion transmissible), sexual
risk behaviour and STD prevention is different in developing countries, the results of this
systematic review cannot be generalized.
Taking into account the limited evidence available, further higher quality research is neces-
sary. There is a clear lack of studies directly comparing MSM and non-MSM donors, and stud-
ies comparing different deferral strategies. When comparing risk factors of infected and non-
infected donors, it is important to describe the studied risk factors in detail and to mention the
donor selection policy used.
The classic triad of evidence-based work consists of the best available evidence, comple-
mented by expert opinion and by preference of the target population [28]. In the absence of
strong evidence it is not surprising that expert opinion and preference (in this case both of pa-
tients and donors) play a greater role in determining policy than they would if the quality of
the evidence were stronger. Donor preference (MSM group) is clear: many demand to be al-
lowed to donate blood because they feel discriminated against [5]. Some do not contest exclu-
sion on the basis of MSM, but rather the lifelong character of the exclusion, noting that it is
applied to no other group on the basis of risk behaviour, except for, for example, intravenous
drug users or commercial sex workers [29]. The preference of the patient population is also
clear: they expect to receive the safest blood possible, but since most people are only future pa-
tients, they tend to be less informed and vocal, with the exception of haemophilia patient
groups, who are both knowledgeable and very concerned about receiving safe blood.
Expert opinion mostly favours exclusion of MSM as the experts also take into account (1)
evidence that is excluded in this systematic review because of its study type (e.g. uncontrolled
studies); (2) evidence from outside the field of transfusion medicine such as higher prevalence
of HIV and other TTI in MSM [1,2]; (3) that the right of the patient to the safest blood possible
has predominance over the wish of a particular donor group to be allowed to donate blood
[30]; (4) the tradition of the sector to make blood ever safer, following the precautionary princi-
ple (stating that, in the interest of public health, risk management action should be taken in the
absence of certainty about risk) rather than the principles of health economics (not reimburs-
ing measures that are not cost-effective) or “risk-based decision making” (implying that risk
management actions should be proportionate to the level of demonstrated risk) [31,32].
Conclusions
In summary, high-quality studies investigating the link between MSM blood donors and TTI
are scarce. The available evidence suggests a link between MSM blood donors and HIV-1 infec-
tion. In one study it was shown that the significant correlation between MSM and HIV-1 infec-
tion was related to recent (< 12 months) MSM contact. This is however very low level evidence
and more high quality studies are needed to be able to unambiguously/clearly recommend a
certain deferral period for MSM. In absence of strong evidence, the length of the exclusion peri-
od mainly depends on regulators’ choices about whether the precautionary principle should
continue to be applied in the blood banking sector or not, and on whether the estimated impact
of exclusion/length of exclusion policy on non-compliance with the donor history question-
naire is greater than the gains made by applying the precautionary principle [26,27,33]. The
scarcity of high-quality evidence within the field of transfusion medicine together with these
choices may explain existing policy differences between countries [27,34].
MSMBlood Donors and TTI
PLOS ONE | DOI:10.1371/journal.pone.0122523 April 15, 2015 13 / 15
Supporting Information
S1 PRISMA Checklist. PRISMA checklist.
(PDF)
S1 File. Search strategies.
(PDF)
S1 Table. List of studies excluded by at least one of the reviewers, including the reason for
exclusion.
(PDF)
Author Contributions
Conceived and designed the experiments: EDB TD VC PV. Analyzed the data: EDB TD. Wrote
the paper: EDB PV. Formulated research question and selection criteria: EDB TD VC PV. Per-
formed the literature search and study selection: EDB TD.
References
1. Friedman MR, Wei C, KlemML, Silvestre AJ, Markovic N, Stall R. HIV infection and sexual risk among
men who have sex with men and women (MSMW): a systematic review and meta-analysis. PLoS One
2014; 9: e87139. doi: 10.1371/journal.pone.0087139 PMID: 24498030
2. Mayer KH, Carballo-Diéguez A. Homosexual and bisexual behavior in men in relation to STDs and HIV
infection. In: Holmes KK, Sparling PF, StammWE, Piot PP, Wasserheit JN, Corey L, et al., editors. Sex-
ually transmitted diseases. New York: McGraw-Hill Professional; 2008. pp. 203–218. PMID:
18091565
3. Vamvakas EC. Why are all men who have had sex with men even once since 1977 indefinitely deferred
from donating blood? Transfusion 2009; 49: 1037–1042. doi: 10.1111/j.1537-2995.2009.02175.x
PMID: 19638153
4. Martucci J. Negotiating exclusion: MSM, identity, and blood policy in the age of AIDS. Soc Stud Sci.
2010; 40: 215–241. PMID: 20527321
5. Roehr B. Should men who have ever had sex with men be allowed to give blood? Yes. BMJ 2009; 338:
b311. doi: 10.1136/bmj.b311 PMID: 19246548
6. Brooks JP. Should men who have ever had sex with men be allowed to give blood? No. BMJ 2009;
338: b318. doi: 10.1136/bmj.b318 PMID: 19246549
7. Benjamin RJ, Bianco C, GoldmanM, Seed CR, Yang H, Lee J, et al. Deferral of males who had sex
with other males. Vox Sanguinis 2011; 101: 339–367. doi: 10.1111/j.1423-0410.2011.01489.x PMID:
21992684
8. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0.
The Cochrane Collaboration. 2011. Available: www.cochrane-handbook.org.
9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-
analyses: the PRISMA statement. PLoS Med. 2009; 6: e1000097. doi: 10.1371/journal.pmed.1000097
PMID: 19621072
10. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and
strength of recommendations. BMJ 2004; 328: 1490. PMID: 15205295
11. Allison RD, Conry-Cantilena C, Koziol D, Schechterly C, Ness P, Gibble J, et al. A 25-year study of the
clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort
of initially asymptomatic blood donors. J Infect Dis. 2012; 206: 654–661. doi: 10.1093/infdis/jis410
PMID: 22740714
12. Alpaugh K, Beckwith DG, Schweder A, Blount-Fronefield D. A donor population classified for viral expo-
sure and infection: Cytomegalovirus and hepatitis B, with an addendum on HTLV-III test results. Labo-
ratory Medicine 1985; 16: 485–488. PMID: 2869588
13. Busch MP, Operskalski EA, Mosley JW, Stevens CE, Schiff ER, Kleinman SH, et al. Epidemiologic
background and long-term course of disease in human immunodeficiency virus type 1-infected blood
donors identified before routine laboratory screening. Transfusion Safety Study Group. Transfusion
1994; 34: 858–864. PMID: 7940656
MSM Blood Donors and TTI
PLOS ONE | DOI:10.1371/journal.pone.0122523 April 15, 2015 14 / 15
14. Christensen PB, Titlestad IL, Homburg KM, Georgsen J, Kristensen T. Hepatitis B core antibodies in
Danish blood donors: a surrogate marker of risk behaviour. Vox Sang. 2001; 81: 222–227. PMID:
11903997
15. Kaldor JM, Archer GT, Buring ML, Ismay SL, Kenrick KG, Lien AS, et al. Risk factors for hepatitis C
virus infection in blood donors: a case-control study. Med J Aust. 1992; 157: 227–230. PMID: 1279364
16. Moore MC, Godfrey GS, Hewitt PE, Barbara JA. Does anti-HBc reactivity reflect 'lifestyle' risk in north
London blood donors? Vox Sang. 1997; 72: 79–84. PMID: 9088074
17. Murphy EL, Bryzman SM, Glynn SA, Ameti DI, Thomson RA, Williams AE, et al. Risk factors for hepati-
tis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study
(REDS). Hepatology 2000; 31: 756–762. PMID: 10706569
18. Neal KR, Jones DA, Killey D, James V. Risk factors for hepatitis C virus infection. A case-control study
of blood donors in the Trent Region (UK). Epidemiol Infect. 1994; 112: 595–601. PMID: 8005225
19. Sanchez AM, Schreiber GB, Nass CC, Glynn S, Kessler D, Hirschler N, et al. The impact of male-to-
male sexual experience on risk profiles of blood donors. Transfusion 2005; 45: 404–413. PMID:
15752159
20. Seed CR, Kiely P, LawM, Keller AJ. No evidence of a significantly increased risk of transfusion-trans-
mitted human immunodeficiency virus infection in Australia subsequent to implementing a 12-month
deferral for men who have had sex with men (CME). Transfusion 2010; 50: 2722–2730. doi: 10.1111/j.
1537-2995.2010.02793.x PMID: 20663106
21. Serfaty L, Giral P, Elghouzzi MH, Jullien AM, Poupon R. Risk factors for hepatitis C virus infection in
hepatitis C virus antibody ELISA-positive blood donors according to RIBA-2 status: a case-control sur-
vey. Hepatology 1993; 17: 183–187. PMID: 8381381
22. Suligoi B, Pupella S, Regine V, Raimondo M, Velati C, Grazzini G. Changing blood donor screening cri-
teria from permanent deferral for men who have sex with men to individual sexual risk assessment: no
evidence of a significant impact on the human immunodeficiency virus epidemic in Italy. Blood Trans-
fus. 2013; 11: 441–448. doi: 10.2450/2013.0162-12 PMID: 23867178
23. Tullen E, De SP, Soulier-Lauper M. ALAT and viral RNA as risk factors in 68 blood donors with anti-hep-
atitis C antibodies. Schweiz MedWochenschr; 1993; 123: 57–61. PMID: 7678939
24. van der Poel C, Cuypers H, Reesink H, Choo QL, Kuo G, Han J, et al. Risk factors in hepatitis C virus-
infected blood donors. Transfusion 1991; 31: 777–779. PMID: 1926325
25. Schmidt M, Nubling CM, Scheiblauer H, Chudy M, Walch LA, Seifried E, et al. Anti-HBc screening of
blood donors: a comparison of nine anti-HBc tests. Vox Sang. 2006; 91: 237–243. PMID: 16958836
26. Seed CR, Lucky TT, Waller D, Wand H, Lee JF, Wroth S, et al. Compliance with the current 12-month
deferral for male-to-male sex in Australia. Vox Sanguinis 2014; 106: 14–22. doi: 10.1111/vox.12093
PMID: 24117918
27. Offergeld R, Kamp C, Heiden M, Norda R, Behr-Gross ME. Sexual risk behaviour and donor deferral in
Europe. Vox Sang. 2014; 107: 420–427. doi: 10.1111/vox.12179 PMID: 25040600
28. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, RichardsonWS. Evidence based medicine: what it
is and what it isn't. BMJ 1996; 312: 71–72. PMID: 8555924
29. Vamvakas EC. Have policy makers been selectively precautionary in indefinitely deferring men who
have sex with men (MSM) from donating blood? In: Vamvakas EC, editor. Decision making in transfu-
sion medicine. Bethesda, MD: AABB Press; 2011. pp. 201–233.
30. Cohen IG, Feigenbaum J, Adashi EY. Reconsideration of the lifetime ban on blood donation by men
who have sex with men. JAMA 2014; 312: 337–338. doi: 10.1001/jama.2014.8037 PMID: 25038346
31. Menitove JE, Leach BJ, Tomasulo P, Katz LM. How safe is safe enough, who decides and how? From
a zero-risk paradigm to risk-based decision making. Transfusion 2014; 54: 753–757. doi: 10.1111/trf.
12569 PMID: 24617628
32. Leiss W, Tyshenko M, Krewski D. Men having sex with men donor deferral risk assessment: an analy-
sis using risk management principles. Transfus Med Rev. 2008; 22: 35–57. PMID: 18063191
33. Slowther A, Watkins NA, Kelly D. Evidence-Based Policy and Practice Leads to Changes in the Criteria
for MSM to Donate Blood. Transfus Med Hemother. 2013; 40: 155–158. doi: 10.1159/000351770
PMID: 23922540
34. Epstein J, Ganz PR, Seitz R, Jutzi M, Schaerer C, Michaud G, et al. A shared regulatory perspective on
deferral from blood donation of men who have sex with men (MSM). Vox Sang. 2014; 107: 416–419.
doi: 10.1111/vox.12166 PMID: 24924302
MSM Blood Donors and TTI
PLOS ONE | DOI:10.1371/journal.pone.0122523 April 15, 2015 15 / 15
